






AUTHOR CORRECTION OPEN



Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Alessandra Fabi , Luisa Carbognin, Andrea Botticelli, Ida Paris , Paolo Fuso, Maria Cristina Savastano, Nicla La Verde , Carla Strina, Rebecca Pedersini, Stefania Guarino, Giuseppe Curigliano , Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone , Giampaolo Tortora, Diana Giannarelli and Giovanni Scambia

npj Breast Cancer (2023)9:89; <https://doi.org/10.1038/s41523-023-00596-1>

Correction to: *npj Breast Cancer* <https://doi.org/10.1038/s41523-023-00579-2>, published online 08 September 2023

In this article, the funding from Roche was inadvertently omitted. Additionally, in the Acknowledgements, the affiliation for Paola Tagliabue was incorrectly provided as 'Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy' and has been corrected to 'Vimercate Hospital, ASST della Brianza, Vimercate, Italy'. The original article has been corrected.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023